An AMCP Market Insights Webinar.

Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care for multiple sclerosis (MS). This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in December 2024. Presenters will examine unmet patient needs in MS, the disease’s underlying pathogenesis, advancements in treatment, and payer perspectives on therapeutic value and evolving diagnostic approaches.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Abeona Therapeutics.

Prademagene Zamikeracel (pz-cel) Pre-Approval Information Exchange and Clinical Trial Data.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

The webinar will highlight the potential challenges in cGVHD management and review of the pivotal study data, follow up data and product profile of REZUROCK.

A Science & Innovation Webinar, sponsored by Abbvie.

The standard of care and refinement of treatment objectives continue to be enhanced by advancements in atopic dermatitis (AD) treatment. The benefits of achieving high treatment targets are now strong enough for medical guidelines to advocate for appropriate use of advanced therapies for AD. In budget constrained environments, payers need to understand how innovations are driving demand for novel mechanisms of action.

An AMCP Market Insights Webinar 

Join us for an engaging webinar exploring key considerations in the management and diagnosis of idiopathic hypersomnia (IH). The presenters will delve into the challenges of distinguishing IH from other sleep disorders, highlight advancements in diagnostic tools, and discuss evolving treatment strategies. Attendees will gain valuable insights into the broader impacts of IH on health outcomes and healthcare systems, with perspectives from clinical and payer experts.

The importance of radiotracer characteristics for diagnosis of coronary artery disease (CAD). FlyrcadoTM (F-18 flurpiridaz) 

The significant clinical and economic burden of CAD highlights the need for accurate and timely diagnosis. Current imaging methods present challenges and limitations that can potentially lead to inconclusive or false results, thereby impacting diagnosis and downstream healthcare resource utilization. 

This webinar will provide a comprehensive overview of current CAD diagnostic imaging, describe the burden of disease, and illustrate limitations and unmet needs posed by existing Myocardial Perfusion Imaging (MPI) modalities in the United States. 

The webinar will then introduce FlyrcadoTM (F-18 flurpiridaz), a recent FDA approved PET-MPI radiotracer indicated to diagnose coronary artery disease (CAD) and discuss how FlyrcadoTM may play a role in optimizing the diagnosis of CAD in some difficult-to-image patient subgroups.